Companion Pharmacogenetic Study to UMCC 9900/9901
Terminated
- Conditions
- Metastatic Breast Cancer
- Registration Number
- NCT00146029
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Brief Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients who participated on UMCC 9900/9901
- Living patients must give written informed consent
Exclusion Criteria
- No tumor block tissue available
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Michigan Cancer Center
🇺🇸Ann Arbor, Michigan, United States